Ponatinib in Advanced NSCLC w/ RET Translocations

NCT01813734 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Ponatinib

Sponsor

Massachusetts General Hospital